

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,

Petitioner,

v.

BAUSCH HEALTH IRELAND LIMITED,

Patent Owner.

Case IPR2022-00722
U.S. Patent No. 7,041,786

PATENT OWNER'S EXHIBIT LIST

Pursuant to 37 C.F.R. § 42.63(e), Patent Owner Bausch Health Ireland

Limited hereby submits a current listing of Patent Owner Exhibits.

EXHIBIT	DESCRIPTION
2001	<i>Bausch Health Ireland Ltd. et al. v. MSN Lab's Private Ltd. et al.</i> , Civil Action No. 2:21-cv-10057 (D.N.J.), ECF No. 51, Amended Scheduling Order, Entered January 5, 2022.
2002	<i>Bausch Health Ireland Ltd. et al. v. Mylan Pharms. Inc.</i> , Civil Action No. 1:22-cv-00020 (N.D. W. Va.), ECF No. 98-1, Parties Proposed Scheduling Order Checklists, Submitted May 16, 2022.
2003	MSN Defendants' First Set of Requests For Production to Plaintiffs (Nos. 1-50), Served on January 11, 2022.
2004	Case Docket of <i>Bausch Health Ireland Ltd. et al. v. MSN Lab's Private Ltd. et al.</i> , Civil Action No. 2:21-cv-10057 (D.N.J.)
2005	Mylan Defendants' First Set of Requests For Production to Plaintiffs (Nos. 1-132), Served on May 19, 2022.
2006	MSN's Notice of Paragraph IV Certification Re: MSN's Plecanatide Tablets, 3mg, U.S. Patent Nos. 7,041,786; 9,610,321; 9,616,097; 9,919,024; 9,925,231; 10,011,637, Dated March 15, 2021 (Excerpt).
2007	Mylan's Notice of Paragraph IV Certification Re: Mylan's Plecanatide Tablets, 3mg, U.S. Patent Nos. 7,041,786; 9,610,321; 9,616,097; 9,919,024; 9,925,231; 10,011,637, Dated March 18, 2021.
2008	Hidaka et al., "In Vitro Disulfide-Coupled Folding of Guanylyl Cyclase-Activating Peptide and Its Precursor Protein," <i>Biochemistry</i> , Vol. 37, No. 23, 8498-8507 (1998).
2009	Hidaka et al., "Dual Function of the Propeptide of Prouroguanylin in the Folding of the Mature Peptide," <i>The Journal of Biological Chemistry</i> , Vol. 275, No. 33, 25155-25162 (2000).

EXHIBIT	DESCRIPTION
2010	Marx et al., "One peptide, two topologies: structure and interconversion dynamics of human uroguanylin isomers," J. Peptide Res. 52, 229-240 (1998).
2011	Chino et al., "Topological isomers of human uroguanylin: interconversion between biologically active and inactive isomers," FEBS Letters, 421, 27-31 (1998).
2012	Hamra, "Uroguanylin: Structure and activity of a second endogenous peptide that stimulates intestinal guanylate cyclase," Proc. Natl. Acad. Sci. USA, Vol. 90, 10464-10468 (1993).
2013	Ironwood Press Release, "Ironwood Pharmaceuticals Promotes Dr. Mark Currie to Senior Vice President, Chief Scientific Officer, and President of R&D," Dated February 11, 2013.
2014	U.S. Patent No. 7,371,727, titled "Methods and Compositions for the Treatment of Gastrointestinal Disorders."
2015	U.S. Patent No. 7,704,947, titled "Methods and Compositions for the Treatment of Gastrointestinal Disorders."
2016	U.S. Patent No. 7,745,409, titled "Methods and Compositions for the Treatment of Gastrointestinal Disorders."
2017	U.S. Patent No. 8,080,526 titled "Methods and Compositions for the Treatment of Gastrointestinal Disorders."
2018	U.S. Patent No. 8,110,553, titled "Methods and Compositions for the Treatment of Gastrointestinal Disorders."
2019	Brancale et al, "Therapeutically targeting guanylate cyclase-C: computational modeling of plecanatide, a uroguanylin analog," Pharma Res Per, Vol. 5, Iss. 2, 1-10 (2017).
2020	Klodt et al., "Synthesis, biological activity and isomerism of guanylate cyclase C-activating peptides guanylin and uroguanylin," J. Peptide Res. 50, 222-230 (1997).

EXHIBIT	DESCRIPTION
2021	International Publication Number WO 01/25266, titled “Uroguanylin as an Intestinal Cancer Inhibiting Agent.”

Respectfully submitted,

Date: June 29, 2022

By: Justin J. Hasford
Justin J. Hasford, Reg. No. 62,180
Bryan C. Diner, Reg. No. 32,409

Finnegan, Henderson, Farabow,
Garrett & Dunner, LLP

Counsel for the Patent Owner

CERTIFICATE OF SERVICE

The undersigned hereby certifies that a copy of the foregoing **Patent Owner's Exhibit List** and **Exhibits 2001-2021** were served electronically via email on June 29, 2022 to counsel of record for the Petitioner at the following:

Jad Mills
Richard Torczon
Nicole Stafford
Dennis Gregory
701 Fifth Avenue, Suite 5100,
Seattle, WA 98104-7036
jmills@wsgr.com
rtorczon@wsgr.com
nstafford@wsgr.com
dgregory@wsgr.com
4863-5899-2145@mail.vault.netdocuments.com

The Petitioner has consented to service by electronic mail.

Dated: June 29, 2022

/Geneva Eaddy/

Geneva Eaddy
Case Manager
FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER LLP